Celltrion has received a nod from Health Canada for biosimilar trastuzumab after the regulator issued a notice of compliance, or marketing authorization, for the Korean firm’s Herzuma version of Roche’s Herceptin.
Herzuma 440mg vials have been approved in Canada for the treatment of adult patients with early breast cancer, metastatic breast...






